AACE endocrinology and diabetes · 2026
Persistent Adrenocortical Insufficiency After Long-Term Metyrapone Treatment for Cushing's Disease.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamagata Satoshi, Kawaguchi Tomohiro, Nakamura Hannah M, Mori Takefumi, Sawada Shojiro, Kageyama Kazunori
Аннотация
INTRODUCTION: Cushing's disease is caused by pituitary tumors that secrete excess adrenocorticotropic hormone (ACTH). Metyrapone is widely used for medical management as a bridge to transsphenoidal pituitary surgery.
CASE REPORT: An 80-year-old man presented with severe hypercortisolemia (101 μg/dL [reference range, 5-23 μg/dL]) and elevated plasma ACTH, 228 pg/mL [reference range, 7.2-63.3 pg/mL]). Initial high-dose dexamethasone suppression and corticotropin-releasing hormone (CRH) tests suggested ectopic ACTH syndrome; however, extensive imaging failed to identify a source. Metyrapone was initiated and escalated to 3000 mg/d, followed by block-and-replacement with hydrocortisone (20 mg/d). After 4 years, repeat CRH testing and dexamethasone suppression supported Cushing's disease. Combined cavernous and inferior petrosal sinus sampling localized ACTH hypersecretion to the right pituitary. Transsphenoidal surgery confirmed a corticotroph pituitary neuroendocrine tumor. Despite tumor resection and metyrapone discontinuation, cortisol levels remained undetectable for more than 1 year.
DISCUSSION: Liquid chromatography-tandem mass spectrometry demonstrated markedly reduced mineralocorticoids, glucocorticoids, and adrenal androgens, indicating global adrenocortical dysfunction. Adrenal androgens are typically increased during metyrapone therapy, suggesting broader effects of long-term metyrapone on adrenal steroidogenesis beyond selective 11β-hydroxylase inhibition. Although postoperative glucocorticoid supplementation may have contributed to adrenal suppression, preserved ACTH responsiveness to CRH supports intact hypothalamic-pituitary signaling with impaired adrenal recovery.
CONCLUSION: This case suggests that prolonged global adrenocortical dysfunction persisting over 1 year after metyrapone discontinuation. Clinicians should be aware of this potential complication and ensure appropriate glucocorticoid replacement and careful long-term monitoring.
CASE REPORT: An 80-year-old man presented with severe hypercortisolemia (101 μg/dL [reference range, 5-23 μg/dL]) and elevated plasma ACTH, 228 pg/mL [reference range, 7.2-63.3 pg/mL]). Initial high-dose dexamethasone suppression and corticotropin-releasing hormone (CRH) tests suggested ectopic ACTH syndrome; however, extensive imaging failed to identify a source. Metyrapone was initiated and escalated to 3000 mg/d, followed by block-and-replacement with hydrocortisone (20 mg/d). After 4 years, repeat CRH testing and dexamethasone suppression supported Cushing's disease. Combined cavernous and inferior petrosal sinus sampling localized ACTH hypersecretion to the right pituitary. Transsphenoidal surgery confirmed a corticotroph pituitary neuroendocrine tumor. Despite tumor resection and metyrapone discontinuation, cortisol levels remained undetectable for more than 1 year.
DISCUSSION: Liquid chromatography-tandem mass spectrometry demonstrated markedly reduced mineralocorticoids, glucocorticoids, and adrenal androgens, indicating global adrenocortical dysfunction. Adrenal androgens are typically increased during metyrapone therapy, suggesting broader effects of long-term metyrapone on adrenal steroidogenesis beyond selective 11β-hydroxylase inhibition. Although postoperative glucocorticoid supplementation may have contributed to adrenal suppression, preserved ACTH responsiveness to CRH supports intact hypothalamic-pituitary signaling with impaired adrenal recovery.
CONCLUSION: This case suggests that prolonged global adrenocortical dysfunction persisting over 1 year after metyrapone discontinuation. Clinicians should be aware of this potential complication and ensure appropriate glucocorticoid replacement and careful long-term monitoring.